# Global Bariatric Surgery Devices Market Analysis and Forecast to 2036 | Expected to Reach US$3.42 Billion as Robotic, Endoscopic, and Revisional Procedures Drive Growth Amid GLP-1 Disruption

- Published: 2026-11-16
- Author: [Healthcare News](https://healthcarenews.io/author/healthcarenews-io.md)
- Topics: [News](https://healthcarenews.io/news.md)
- Source: https://healthcarenews.io/news/global-bariatric-surgery-devices-market-analysis-and-forecast-to-2036-expected-to-reach-us/
- Publication: Healthcare News
- Publisher: Connectively (Terkel, Inc.)
- Editorial policy: https://healthcarenews.io/editorial-policy/

Dublin, Nov. 16, 2026 [(GLOBE NEWSWIRE)](https://www.globenewswire.com) -- <a href="https://www.researchandmarkets.com/reports/6288383/bariatric-surgery-devices-market-global-forecast?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=kmsjdf&amp;utm_campaign=2399888+-+Global+Bariatric+Surgery+Devices+Market+Analysis+and+Forecast+to+2036+%7c+Expected+to+Reach+US%243.42+Billion+as+Robotic%2c+Endoscopic%2c+and+Revisional+Procedures+Drive+Growth+Amid+GLP-1+Disruption&amp;utm_exec=jocamsai" rel="nofollow">"Bariatric Surgery Devices Market - Global Forecast to 2036"</a> has been added to **ResearchAndMarkets.com's** offering.

The global bariatric surgery devices market was valued at USD 2.10 billion in 2025 and is estimated to reach USD 2.18 billion in 2026. Revenue is projected to increase to USD 3.42 billion by 2036, representing a CAGR of 4.6% during the 2026-2036 forecast period. The report evaluates procedure volumes, GLP-1 medication use, clinical evidence, technology developments, reimbursement, regulation, pricing, competition, and the industry value chain.

The market includes stapling devices, reloads and staple-line reinforcement, energy devices, trocars, retractors, suturing and closure tools, endoscopic bariatric devices, intragastric balloons, adjustable gastric bands, and robot-specific instruments. Covered procedures include sleeve gastrectomy, Roux-en-Y gastric bypass, one-anastomosis gastric bypass, duodenal switch, SADI-S, revisional surgery, and endoscopic sleeve gastroplasty.

**Obesity Prevalence and Clinical Outcomes Support Long-Term Demand**

Demand for bariatric surgery devices is supported by a substantial untreated population. The World Health Organization reported that 890 million adults were living with obesity in 2022, while the ASMBS estimates that fewer than 1% of eligible patients undergo surgery annually. Research presented at the ASMBS 2026 meeting also found that 90% to 95% of nearly 20 million U.S. patients received no obesity treatment between 2018 and 2025.

GLP-1 medications have reduced near-term surgical volumes. American College of Surgeons figures presented in May 2026 showed that procedures at accredited U.S. centers declined to slightly more than 177,000 in 2024, down 23% from the 2022 peak of over 230,000. However, a study of 51,085 patients by NYU Langone Health and NYC Health + Hospitals reported 24% total weight loss two years after surgery, compared with 4.7% among patients treated with semaglutide or tirzepatide. Researchers also reported that up to 70% of patients may discontinue GLP-1 therapy within one year.

Expanded clinical eligibility is expected to support future demand. The 2022 ASMBS and IFSO guidelines recommend surgery for patients with a BMI of 35 or higher regardless of comorbidities, support consideration at a BMI of 30 to 34.9 with metabolic disease, reduce the threshold to 27.5 for Asian patients, and endorse treatment for selected adolescents.

**GLP-1 Competition Reshapes Bariatric Procedure Volumes**

GLP-1 substitution remains the market's leading restraint. Epic Cosmos data showed bariatric cases declining from 42,615 in 2023 to 33,429 in 2025 as GLP-1 prescriptions exceeded 1.42 million. Intuitive Surgical also reported high single-digit declines in U.S. bariatric da Vinci procedures for six consecutive quarters. Prior authorization, supervised weight-loss requirements, public-sector waiting lists, out-of-pocket costs, patient concerns, and stigma continue to restrict access.

Demand for intragastric balloons and gastric bands is also weakening. ASMBS estimates indicate that U.S. balloon procedures declined from 4,358 in 2022 to 1,461 in 2023. Manufacturers must therefore adapt product portfolios, improve procedure forecasting, support combined medication and surgery pathways, and demonstrate the clinical and economic value of endoscopic treatment.

**Revisional, Endoscopic, and Robotic Procedures Create Growth Opportunities**

Revisional surgery is expected to generate attractive opportunities as patients with weight regain or reflux undergo conversion from sleeve gastrectomy to gastric bypass. These complex cases typically require additional reloads, reinforcement products, suturing tools, and energy devices.

Endoscopic treatment is another high-growth area. The FDA granted an endoscopic sleeve gastroplasty indication for Apollo Endosurgery's suturing system in July 2022, while Boston Scientific acquired Apollo in 2023. The MERIT trial published in The Lancet reported 13.6% total weight loss with endoscopic sleeve gastroplasty at 52 weeks, strengthening the supporting evidence.

The procedure mix is also changing. American College of Surgeons data showed that sleeve gastrectomy's share of U.S. procedures declined from 64% in 2020 to 58% in 2024, while gastric bypass increased from 28% to 33%. Sleeve gastrectomy is expected to remain the leading procedure in 2026, but revisional surgery is forecast to record the fastest growth.

**Market Segment and Regional Outlook**

-   **Products:** Stapling devices are expected to lead in 2026 because sleeve, bypass, and revision procedures require multiple reloads, with powered and robotic systems commanding higher prices. Endoscopic bariatric devices are projected to achieve the highest CAGR.
-   **Approaches:** Laparoscopic surgery is expected to retain the largest share, supported by established clinical infrastructure and surgeon experience. Robotic-assisted surgery is forecast to grow fastest as bypass and revisional volumes increase.
-   **End users:** Hospitals are expected to lead due to their accredited programs, inpatient capacity, and ability to manage complex cases. Ambulatory surgery centers are projected to grow rapidly through outpatient sleeve and endoscopic procedures.
-   **Regions:** North America is expected to hold the largest market share in 2026, supported by high procedure volumes, advanced stapling systems, robotic adoption, and established reimbursement. Asia-Pacific is projected to record the highest CAGR due to expanding bariatric capacity, large populations with obesity and type 2 diabetes, and relatively high GLP-1 treatment costs.

Europe remains a significant market, supported by publicly funded surgery and limited reimbursement for weight-loss medications in several countries. Latin America benefits from established programs in Brazil, Mexico, Colombia, Argentina, and Chile. The Middle East & Africa is expected to expand through high-volume programs in Kuwait, Saudi Arabia, Qatar, and the UAE, alongside bariatric medical tourism in Turkiye.

**Competitive Landscape**

The bariatric surgery devices market is moderately consolidated. Competition centers on staple-line security, powered and smart staplers, robotic platform compatibility, outcomes data, surgeon training, and hospital contract pricing. Investment is increasing in next-generation staplers, reinforcement materials, robotic instruments, and endoscopic suturing systems.

Companies profiled in the report include Medtronic plc, Johnson & Johnson MedTech (Ethicon), Intuitive Surgical, Inc., Teleflex Incorporated, CONMED Corporation, Applied Medical Resources Corporation, B. Braun Melsungen AG, KARL STORZ SE & Co. KG, Boston Scientific Corporation, Olympus Corporation, Cook Medical LLC, Allurion Technologies, Inc., ReShape Lifesciences Inc., Spatz Medical, Reach Surgical, Inc., and Fengh Medical Co., Ltd.

The report provides market forecasts through 2036, evaluates GLP-1 effects on bariatric procedure demand, identifies high-growth product and regional opportunities, and benchmarks leading bariatric device companies. Its findings support product development, pricing, investment, market entry, portfolio planning, and competitive strategy across the global bariatric surgery devices industry.

For more information about this report visit <a href="https://www.researchandmarkets.com/reports/6288383/bariatric-surgery-devices-market-global-forecast?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=kmsjdf&amp;utm_campaign=2399888+-+Global+Bariatric+Surgery+Devices+Market+Analysis+and+Forecast+to+2036+%7c+Expected+to+Reach+US%243.42+Billion+as+Robotic%2c+Endoscopic%2c+and+Revisional+Procedures+Drive+Growth+Amid+GLP-1+Disruption&amp;utm_exec=jocamsai" rel="nofollow">https://www.researchandmarkets.com/r/z6qu4l</a>

**About ResearchAndMarkets.com**  
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: 
CONTACT: ResearchAndMarkets.com 
         Laura Wood,Senior Press Manager 
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470 
         For U.S./ CAN Toll Free Call 1-800-526-8630 
         For GMT Office Hours Call +353-1-416-8900 

  
![](https://ml.globenewswire.com/media/Y2QxMGExZDQtNWJiNC00ZmFjLTk3NmUtYjIzYWUzZWU1N2E1LTEwMjY3MzctMjAyNi0xMS0xNi1lbg==/tiny/Research-and-Markets.png)

## Related

- [Global Medical AI Apps Market Size and Forecast by Application, End Use and Region (2026-2033) | 19.1% CAGR Fueled by Digital Health and Personalized Care](https://healthcarenews.io/news/global-medical-ai-apps-market-size-and-forecast-by-application-end-use-and-region-2026-203.md)
- [Cell Line Development - Global Strategic Business Report 2026-2032: Capitalize on 10.1% CAGR](https://healthcarenews.io/news/cell-line-development-global-strategic-business-report-2026-2032-capitalize-on-10-1-cagr.md)
- [Daré Bioscience Receives Approximately $852,000 in Additional Grant Funding](https://healthcarenews.io/news/dare-bioscience-receives-approximately-852-000-in-additional-grant-funding.md)
- [INVO Fertility Reports Third Quarter 2026 Results Highlighting 28% Clinic Revenue Growth and Continued Positive Clinic-Level Adjusted EBITDA](https://healthcarenews.io/news/invo-fertility-reports-third-quarter-2026-results-highlighting-28-clinic-revenue-growth-an.md)
